proteins, such as myeloperoxidase or neutrophil elastase, to trap and kill microorganisms. 8, 9 Extracellular DNA traps have been linked to several diseases, including sepsis, 10 small-vessel vasculitis, 11 or preeclampsia. 12 Other studies showed that both extracellular DNA traps and VWF are significantly involved in deep vein thrombosis. 6, [13] [14] [15] It has been demonstrated that there is a correlation between levels of circulating nucleosomes, activated neutrophils, and the occurence of deep vein thrombosis. 16 Also, immunostained sections of venous thrombi from animal models indicate a connection of inflammation and thrombosis by the fact that both NETs and VWF seem in close proximity to each other. 13, 14 This association of both molecules was linked to the capability of VWF to bind histones. 17 Here we show that VWF and pure, isolated DNA from human whole blood are able to interact in a shear-dependent manner, but independently of histones or other proteins. We examined the interaction of ultralarge VWF and extracellular DNA traps under flow conditions and analyzed the characteristics of the binding process by applying an immunobased binding assay and immunostaining. We hypothesize that VWF, by binding DNA, might act as a linker for leukocyte adhesion to the endothelium and thereby underline the role of VWF in inflammation, besides its function in platelet adhesion.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

DNA Binds to VWF Under Shear Conditions
To investigate whether VWF can bind to isolated DNA molecules, we studied the binding of DNA to physiologically released ultralarge VWF fibers on a histamine-stimulated, confluent endothelial cell layer under shear flow conditions of 2 to 20 dyne/cm 2 . Additionally, we applied a microfluidic channel system using VWF functionalized surfaces, which were perfused with pure, isolated DNA from whole blood. Protein contamination of isolated DNA was excluded by
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a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13
NET neutrophil extracellular trap VWF von Willebrand factor Figure 1 . DNA binds to von Willebrand factor (VWF) under shear conditions. A, Protein-free DNA was perfused at 10 dyne/cm 2 over a histamine-stimulated, intact endothelial cell layer (thereby releasing VWF fibers) and labeled with Sytox Green (visualized in red). DNA colocalized with released VWF strings (arrowheads). Also, nuclei of human umbilical vein endothelial cells were stained during the fixation process because of excessive dye in the supernatant. Green indicates VWF; and red, DNA. Scale bar, 10 μm. B, Isolated DNA was perfused over a functionalized VWF surface at 2 dyne/cm 2 . 4′,6-Diamidino-2-phenylindole-labeled DNA (visualized in red) binds to VWF fibers only (green), but not globular, nonactivated VWF, under flow conditions. Scale bar, 50 μm. C, Binding of DNA to VWF is Ristocetindependent; increasing DNA concentrations (0-5 μg/mL) were incubated with 1 μg/mL VWF in the presence (solid line) or absence (dotted line) of 1.5 mg/mL Ristocetin. The binding of DNA to VWF was assessed by fluorescence intensity measurments using Sytox Green labeling. Data are expressed as mean±SD (*P<0.05; n=6).
absorbance measurements of 260/280 nm ratio, Bradford assay, and gel electrophoresis. In both cases, immunofluorescence staining showed a clear colocalization of perfused DNA with either cellular-released VWF fibers or surface-coated VWF (Figure 1A and 1B; Movie I in the online-only Data Supplement). DNA did not interact with BSA-coated surfaces or globular, nonactivated VWF (data not shown). No difference in binding could be observed at different levels of shear stress between 2 and 20 dyne/cm 2 , so we assumed that already 2 dyne/cm 2 is sufficient to promote DNA-VWF interaction (data not shown). These results indicate that DNA is able to bind directly to VWF under shear conditions without the involvement of other proteins.
To characterize the binding of DNA to VWF in more detail, we performed an immunobased quantitative assay with and without Ristocetin, an antibiotic thought to expose the binding sites of the A1-domain of VWF in the absence of high shear forces. 18 Both DNA and VWF molecules were incubated in increasing DNA/VWF ratios in the absence or presence of Ristocetin at different concentrations, and DNA binding was examined. DNA binding to VWF was only detectable when both molecules were coincubated with 1.5 mg/mL Ristocetin ( Figure 1C ) and decreased with descending Ristocetin concentrations ( Figure I in the online-only Data Supplement). These data are in line with our abovementioned data and demonstrate that DNA binding to VWF is dependent on an exposed VWF A1-domain and occurs only on activated, but not on globular, VWF.
GP1bα-Binding Site of VWF A1-Domain Is Blocked by DNA
As mentioned above, isolated DNA directly binds to VWF in a shear-or Ristocetin-dependent manner. Therefore, we next analyzed the binding capacity of DNA to recombinant VWF A1-domain and the effect of DNA-VWF interaction on other binding partners of VWF. As shown in Figure 2A , DNA is able to bind to an isolated A1-domain in the presence of Ristocetin. Previous studies proved that the binding of large polyanionic molecules, such as heparin, to VWF leads to a decreased adhesion of platelets. 19 Therefore, we studied the effect of the polyanionic DNA on platelet-VWF binding. Perfusion of platelet-rich plasma over a DNA-preincubated VWF surface demonstrated that the binding of platelets to VWF was significantly impaired by 78% (±6.8%) compared with control experiments lacking DNA ( Figure 2B and 2C) . Furthermore, this DNA blockage could not only be observed on a wild-type VWF coating but also on an A1-domain functionalized channel (see Figure 2B ). The subsequent reduction in platelet binding is comparable with the amount of adhesion on a VWF-mutant protein that lacks the A1-domain ( Figure 2B ). However, the rolling velocity of residual platelets on the DNA-bound wildtype VWF surface remained unchanged (data not shown). Although these in vitro flow experiments are somewhat artificial, this result indicates a hindrance in VWF-platelet interaction because of a blockage of the GP1bα-binding site in the VWF A1-domain by DNA. However, it should be mentioned that under physiological conditions, in which other blood components such as erythrocytes are present, this blockage can be restored in a hematocrit-dependent manner because of the rheological distribution of the platelets ( Figure IIA and IIB in the online-only Data Supplement). This phenomenon has also been described in a previous work, where it was shown that the adhesion probability of platelets to VWF is strongly dependent on hematocrit.
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DNA Binding to VWF Is Blocked by Heparin
Because of our previous results, we hypothesized that the VWF A1-domain is mainly involved in the binding process of DNA to VWF. To delineate the contribution of heparinbinding sites in the A1-domain, we assessed whether DNA binding to VWF can be blocked using unfractionated heparin. Therefore, plasmatic VWF was immobilized on a microfluidic Figure 2 . Glycoprotein 1bα-binding site is blocked by DNA. A, DNA directly binds to the recombinant von Willebrand factor (VWF) A1-domain. Increasing DNA concentrations (0-5 μg/mL) were incubated with 1 μg/mL VWF A1-domain in the presence (solid line) or absence (dotted line) of 1.5 mg/mL Ristocetin. The binding of DNA to VWF A1-domain was assessed by fluorescence intensity measurments using Sytox Green labeling. Data are expressed as mean±SD (*P<0.05; n=3). B, Quantification of platelets adhering to a VWF wild-type (WT) surface that was blocked with DNA shows a significant reduction by 78% (±6.8%) in platelets binding to VWF. In addition, platelet binding to the A1-domain was completely blocked by DNA. delA1, delA2, and delA3 indicate VWF proteins that lack the A1-, A2-, and A3-domains, respectively. Data are expressed as mean±SD (*P<0.05; n=3-6). C, Platelet-rich plasma was perfused over a VWF surface that was blocked with 10 μg/mL isolated DNA. Adhering platelets were stained using an anti-GP1bα antibody. White indicates platelets. Scale bar, 50 μm.
channel and was preincubated with 50 U/mL unfractionated heparin before perfusion with isolated DNA. Indeed, immunofluorescence staining confirmed that the binding of DNA to VWF was completely abolished compared with a control channel ( Figure 3A and 3B ). Because the DNA was proven to be protein-free, the involvement of histones could be excluded. DNA that was once immobilized on a VWF surface could be removed with DNAse I, but not with heparin ( Figure IIIA and IIIB in the online-only Data Supplement), indicating that the binding occurs with a high affinity. This result could also be accomplished in an ELISA-based binding assay ( Figure IIIC in the online-only Data Supplement).
In addition, we analyzed whether autogenic DNA of Staphylococcus aureus-or phorbol 12-myristate 13-acetate (PMA)-stimulated neutrophils from whole blood can attach to a VWF functionalized surface under flow conditions, and whether this interaction can be blocked by heparin. For this experiment, neutrophils were stimulated to release NETs and afterward perfused over a microfluidic channel. In the control channel, both S. aureus-(data not shown) and PMA-treated neutrophils released a massive network of DNA fibers, which were captured by the VWF surface. Thereby, the DNA meshwork and several neutrophilic cells were immobilized on the surface, and secondary neutrophils were trapped ( Figure 3C ). Perfusion of 100 U/mL DNAse I over the formed DNA network completely dismanteled all DNA fibers and removed all attaching neutrophils (Movie II in the online-only Data Supplement). However, if the VWF-coated surface was blocked with 50 U/mL heparin beforehand, neutrophils that released their DNA could not attach to the surface, and leukocyte adhesion to VWF was almost completely impaired ( Figure 3D ). Because, for this experiment, it was an autogenic release of NETs from neutrophils, an involvement of histones cannot be excluded in this case. Nevertheless, this shows that heparin is able to block the DNA and leukocyte binding to VWF, indicating the same binding site of heparin and DNA within the A1-domain.
Inhibition Efficiency of DNA-VWF Binding Varies for Different Heparins
Using the abovementioned immunobased assay together with Ristocetin, we applied different commercially available heparins to block DNA binding to VWF in vitro. Unfractionated heparin almost completely inhibited DNA-VWF interaction, whereas low-molecular-weight heparins such as Tinzaparin (6.5 kDa on average) or Fondaparinux (a pentasaccharide) Figure 3 . Binding of DNA to von Willebrand factor (VWF) is blocked by heparin. A, Isolated DNA was perfused over a VWF surface. Bound DNA was visualized with 4′,6-diamidino-2-phenylindole (visualized in red). Immunofluorescence staining shows a decrease in DNA binding after blockage of the surface with 50 U/mL heparin compared with a 2% BSA-blocked control surface. Green indicates VWF; and red, DNA. Scale bar, 50 μm. B, Quantification of adhering DNA on a VWF channel that was blocked with heparin. Data are expressed as mean±SD (*P<0.05; n=5). C, Isolated and phorbol 12-myristate 13-acetate-stimulated leukocytes were perfused through 2 opposing VWF channels. Autolog-released DNA from leukocytes was not able to be immobilized on a VWF surface that has previously been blocked with 50 U/mL heparin (channel 1). Blocking with 2% BSA had no influence on DNA adhesion to VWF (channel 2). were less effective ( Figure 4A and 4B) . Preincubation of VWF with Tinzaparin significantly reduced the binding of DNA, whereas Fondaparinux, the smallest heparin available, kept DNA-VWF binding unchanged. After partial digestion of unfractionated heparin using heparinase I, the DNA-VWF interaction could be restored ( Figure 4C and 4D) . These results indicate that an inhibition of DNA-VWF binding depends on the length of negatively charged molecules. To further confirm the charge-dependent interaction of negative DNA with the positive A1-domain, we neutralized the negative charge of the DNA by polycationic chitosan. It is well known that chitosans are able to interact with polyanions such as DNA. 21 Indeed, chitosan-mediated blockage of negative charges on DNA inhibits its binding to VWF in a concentration-dependent manner (Figure V in the online-only Data Supplement), which strengthens our hypothesis that DNA binding to VWF is primarily charge-based.
VWF A1-Domain Is a Potential Binding Site for DNA
Experiments suggest a competitive binding between GP1bα, heparin, and DNA to VWF. Because binding sites of GP1bα Figure 4 . Binding of DNA to von Willebrand factor (VWF) is blocked by low-molecular-weight heparins. A, Increasing concentrations (0-5 μg/mL) of DNA were incubated with 1 μg/mL VWF, which was preincubated with 50 U/mL unfractionated heparin (UFH), 50 U/mL Tinzaparin, or 29 μg/mL Fondaparinux (both low-molecular-weight heparins). Binding of DNA to VWF was assessed by Sytox Green fluorescence intensity increase. The dotted box is represented as a bar graph in B to indicate significant blockage. B, Preincubation of VWF with UFH and Tinzaparin, but not with Fondaparinux, causes a significant decrease in DNA binding. Data are expressed as mean±SD (*P<0.05; n=3). C, Increasing concentrations (0-5 μg/mL) of DNA were incubated with 1 μg/mL VWF, which was preincubated with 50 U/ mL UFH, or UFH that has been digested by heparinase I beforehand. Binding of DNA to VWF was assessed by Sytox Green fluorescence intensity increase. The dotted box is represented as a bar graph in D to indicate significant blockage. D, Preincubation of VWF with UFH causes a significant decrease in DNA binding, which can be restored by partial heparinase I digestion of UFH. Data are expressed as mean±SD (*P<0.05; n=3). and heparin are located within the A1-domain, we calculated the electrostatic potential produced by this domain to search for positively charged regions where the negatively charged DNA could potentially bind. The electrostatic potential revealed a positively charged region at the A1-domain ( Figure 5A ), which remained approximately constant during the course of a 195-ns molecular dynamics simulation ( Figure  IVA in the online-only Data Supplement). This positively charged area intersects with a part of the GP1bα-binding site (compare blue in Figure 5A with orange in Figure 5B ) and contains the residues associated with the heparin-binding site (compare blue in Figure 5A with green in Figure 5C ). This suggests that DNA interacts with VWF at the same regions that GP1bα and heparin do.
DNA Does Not Block the Cleavage Site for ADAMTS13
Because we found that DNA binds to the VWF A1-domain, we intended to ascertain whether this interaction could possibly block also parts of the A2-domain, which contains the cleavage site for ADAMTS13. Therefore, we performed in vitro flow experiments for DNA binding to VWF fibers released by a confluent human umbilical vein endothelial cell layer with or without the addition of ADAMTS13. After immunofluorescence staining, we could see that even in the presence of DNA, VWF fibers were removed by ADAMTS13 activity (Figure 6A and 6B). Although we saw the same amount of fibers in the end point observation of the microfluidic experiments, we observed a decreased cleavage capacity of ADAMTS13 in the time course of an ELISA activity ( Figure 6C ). In addition, electrostatic potential calculations revealed that the surface around the A2-domain is mostly negatively charged (see Figure IVB in the online-only Data Supplement), which may disfavor the interaction of this domain with DNA. Surprisingly, in the presence of DNA, more VWF fibers were detectable. Using DNAse I, the increase in VWF string formation could be significantly reduced ( Figure 6A ). The latter results indicate that the DNA may support the activation and stabilization of VWF fibers on shear flow conditions, similar to previous results where platelet-bound VWF has been shown to be a better ADAMTS13 substrate.
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Discussion
In this work, we could show that protein-free DNA is able to directly bind to VWF. Our data extend to the already existing in vivo measurements in deep vein thrombosis mouse models, that plasma DNA levels are increased and that VWF and DNA released by leukocytes (NETs) overlap in thrombus sections. 13, 14 However, these previous findings were correlated to the observation that proteins such as histones are still present on the autolog-released NETs and that these proteins are then able to interact with VWF. 17 In contrast, our findings demonstrate that the colocalization of VWF with DNA is not necessarily dependent on other proteins, but instead pure isolated DNA, which is protein-and RNA-free, is able to bind directly to VWF and mediate leukocyte adhesion under physiological blood flow conditions ( Figures 1A and 3C) . Consequently, the DNA-VWF interaction could not only lead to thrombus formation but additionally promote leukocyte extravasation. In this context, it was recently demonstrated that blocking of VWF decreases leukocyte extravasation in different inflammatory mouse models and in immune complex-mediated vasculitis, which may open a new anti-inflammatory treatment option. 23, 24 What is more, we previously showed that S. aureus itself binds to the VWF A1-and A3-domains, which supports S. aureus adhesion to the vessel wall and, in turn, can be blocked using heparin. 25 Besides this process, DNA release by leukocytes can be induced by S. aureus infection. Hence one may imagine a scenario where S. aureus-induced NET formation leads to DNA-VWF-Staphylococcus binding, followed by leukocyte adhesion to the vessel wall and consecutive extravasation. Furthermore, a deficiency in the VWF-regulating enzyme, ADAMTS13, leads to an increased leukocyte adhesion and enhanced extravasation of neutrophils. 26 The binding of leukocyte-derived extracellular DNA to VWF, therefore, represents a new possibility for leukocytes to be recruited to the vessel wall, besides the suggested direct binding to VWF via P-selectin glycoprotein ligand-1 and β2 integrins. 27 However, our data show that this interaction strongly depends on shear flow. Uncoiling of the VWF molecule occurs under flow conditions above a critical shear rate, 28 which can expose binding sites such as the A1-domain. In the absence of flow conditions, Ristocetin is an antibiotic to mimic this statefunction relationship without the application of shear flow in an in vitro setup. In both cases, we could detect a binding of DNA to VWF; however, if both prerequisites are absent, an interaction of the molecules is not possible. These findings suggest that DNA binds only to an uncoiled VWF and, therefore, to its A1-domain.
Our studies suggest that binding occurs via electrostatic interactions between the polyanionic molecule (DNA) and the positively charged VWF A1-domain, but has no effect on the VWF A2-domain, because the specific enzyme, ADAMTS13, is still able to cleave VWF fibers. It is well known that the A1-domain of VWF exhibits a main role in the function of the large VWF molecule. Many binding sites are buried at this location, especially the binding sites for both platelet GP1bα and heparin. All these partners, examined in our experiments, are negatively charged or have at least several negatively charged residues, so that they may be classified as polyanionic molecules that are able to bind to the positively charged VWF A1-domain. 7 In particular, the phosphate groups of the DNA backbone and the sulfate groups linked to the heparin sugars make up the similar polyanionic character of both biopolymers. However, low-molecular-weight heparins and heparinase-digested unfractionated heparin instead show less capability to block DNA-VWF binding, which suggests that the impaired interaction is because of molecule size and the amount of negative charges.
Heparins are known to be multifunctional glycosaminoglycans, which are preferred anticoagulants for venous thromboembolism treatment and the first choice of therapy for venous thromboembolism in patients with cancer. 29 The classic mode of action is that heparins are able to bind antithrombin III and thereby accelerate the blockage of thrombin and mainly factor Xa. However, as shown in this work, heparins are also able to directly interact with VWF, thereby blocking DNA binding to VWF, which demonstrates that the prothrombotic effect of extracellular DNA traps 6, 13, 14 could be diminished by heparin. In conclusion, our data add a new aspect to the anticoagulatory mechanisms of heparin, which may further explain the beneficial effect of heparin in the treatment of venous thromboembolism, expecially in patients suffering from cancer.
Our experiments propose a new general function of the VWF molecule, namely to act as a polyanion-binding molecule after uncoiling by interacting with highly negatively charged molecules such as heparin or DNA, however being nonspecific but with a high affinity. This DNA-VWF interaction may play a pivotal role in leukocyte adhesion and extravasation on inflammation and coagulatory conditions. . DNA binding does not inhibit von Willebrand factor (VWF) cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). A, DNA significantly increases the amount of VWF strings in the absence of ADAMTS13, which can be prevented by DNAse I. However, both in the presence and absence of DNA on VWF fibers, the number of VWF fibers per field of view is significantly decreased by ADAMTS13. There is no significant difference in the amount of strings after the addition of ADAMTS13 in both cases. Data are expressed as mean±SD (*P<0.05; n=3). B, Immunofluorescence images showing that even in the presence of DNA, ADAMTS13 is able to cleave VWF fibers at 10 dyne/cm 2 . Without ADAMTS13, large VWF strings are visible on human umbilical vein endothelial cells. These fibers are degraded in the presence of ADAMTS13. White indicates VWF. Scale bar, 50 μm. C, ADAMTS13 activity was measured using an ELISA that quantifies cleavage by glutathion-S-transferase-tagged VWF73 (GST-VWF73) products. In the presence of DNA, ADAMTS13 cleavage is slowed down (open dots) but, however, reaches the same level after 30 min as without DNA (filled dots).
It was recently shown that von Willebrand factor-DNA interaction plays an important role in inflammation and deep vein thrombosis. Using advanced microfluidics, molecular biological tools, and electrostatic potential calculations, the present work unravels the molecular mechanism of this interaction. We could show, for the first time to our knowledge, that isolated, pure (protein-free) DNA binds to the A1-domain of von Willebrand factor, which can be blocked by heparins. Hence, heparin treatment might be of superior benefit for patients with thrombosis known to exhibit high amounts of DNA and von Willebrand factor, as also reflected in recent therapeutic guidelines for cancer-related thrombosis. Therefore, our study emphasizes the effect of von Willebrand factor's binding capacity to highly negatively charged molecules and considerably underlines the role of von Willebrand factor in both inflammation and thrombosis.
Significance
